Linezolid versus vancomycin for skin and soft tissue infections

Jirong Yue; Bi Rong Dong; Ming Yang; Xiaomei Chen; Taixiang Wu; Guan J Liu

doi:10.1002/14651858.CD008056.pub3

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Respuestas clínicas Cochrane
Guías
Temas

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Clinical cure, Outcome 1 All participants.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Clinical cure, Outcome 2 Adults' subgroup (≥ 18 years).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Clinical cure, Outcome 3 MRSA subgroup.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.1

Comparison 2 Microbiological cure, Outcome 1 All participants.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.2

Comparison 2 Microbiological cure, Outcome 2 Adults' subgroup (≥ 18 years).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 2.3

Comparison 2 Microbiological cure, Outcome 3 MRSA subgroup.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 3.1

Comparison 3 Mortality, Outcome 1 All‐cause mortality during follow‐up.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.1

Comparison 4 Adverse events, Outcome 1 Anaemia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.2

Comparison 4 Adverse events, Outcome 2 Diarrhoea.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.3

Comparison 4 Adverse events, Outcome 3 Red man syndrome.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.4

Comparison 4 Adverse events, Outcome 4 Pruritus.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.5

Comparison 4 Adverse events, Outcome 5 Rash.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.6

Comparison 4 Adverse events, Outcome 6 Thrombocytopenia.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.7

Comparison 4 Adverse events, Outcome 7 Headache.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.8

Comparison 4 Adverse events, Outcome 8 Nausea.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 4.9

Comparison 4 Adverse events, Outcome 9 Vomiting.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 5.1

Comparison 5 Duration of treatment, Outcome 1 Duration of treatment (day).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. Clinical cure

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All participants Show forest plot	9	3114	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [1.03, 1.16]

2 Adults' subgroup (≥ 18 years) Show forest plot	5	2402	Risk Ratio (M‐H, Random, 95% CI)	1.16 [1.02, 1.32]

3 MRSA subgroup Show forest plot	6	2659	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [1.03, 1.17]

Comparison 1. Clinical cure

Ir a la tabla de la revisión

Comparison 2. Microbiological cure

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All participants Show forest plot	9	2014	Risk Ratio (M‐H, Random, 95% CI)	1.08 [1.01, 1.16]

2 Adults' subgroup (≥ 18 years) Show forest plot	5	1458	Risk Ratio (M‐H, Random, 95% CI)	1.17 [1.02, 1.34]

3 MRSA subgroup Show forest plot	6	1289	Risk Ratio (IV, Random, 95% CI)	1.17 [1.04, 1.32]

Comparison 2. Microbiological cure

Ir a la tabla de la revisión

Comparison 3. Mortality

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All‐cause mortality during follow‐up Show forest plot	3	2352	Risk Ratio (M‐H, Fixed, 95% CI)	1.44 [0.75, 2.80]

Comparison 3. Mortality

Ir a la tabla de la revisión

Comparison 4. Adverse events

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia Show forest plot	2	1300	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.33, 1.62]

2 Diarrhoea Show forest plot	3	2352	Risk Ratio (IV, Random, 95% CI)	1.78 [0.81, 3.88]

3 Red man syndrome Show forest plot	2	1172	Risk Ratio (M‐H, Fixed, 95% CI)	0.04 [0.01, 0.29]

4 Pruritus Show forest plot	3	2352	Risk Ratio (M‐H, Fixed, 95% CI)	0.36 [0.17, 0.75]

5 Rash Show forest plot	3	2352	Risk Ratio (M‐H, Fixed, 95% CI)	0.27 [0.12, 0.58]

6 Thrombocytopenia Show forest plot	2	1300	Risk Ratio (IV, Fixed, 95% CI)	13.06 [1.72, 99.22]

7 Headache Show forest plot	2	2232	Risk Ratio (IV, Fixed, 95% CI)	1.23 [0.59, 2.61]

8 Nausea Show forest plot	2	2232	Risk Ratio (M‐H, Fixed, 95% CI)	2.45 [1.52, 3.94]

9 Vomiting Show forest plot	2	2232	Risk Ratio (M‐H, Fixed, 95% CI)	2.20 [0.96, 5.04]

Comparison 4. Adverse events

Ir a la tabla de la revisión

Comparison 5. Duration of treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Duration of treatment (day) Show forest plot	1	1180	Mean Difference (IV, Fixed, 95% CI)	0.90 [0.32, 1.48]

Comparison 5. Duration of treatment

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet